Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia

Charlotte M. Niemeyer, Mignon L. Loh, Annamaria Cseh, Todd Cooper, Christopher C. Dvorak, Rebecca Chan, Blanca Xicoy, Ulrich Germing, Seiji Kojima, Atsushi Manabe, Michael Dworzak, Barbara De Moerloose, Jan Starý, Owen P. Smith, Riccardo Masetti, Albert Catala, Eva Bergstraesser, Marek Ussowicz, Oskana Fabri, André BaruchelHélène Cavé, Michel Zwaan, Franco Locatelli, Henrik Hasle, Marry M. Van Den Heuvel-Eibrink, Christian Flotho, Ayami Yoshimi

Onderzoeksoutput: Bijdrage aan tijdschriftArtikelpeer review

36 Citaten (Scopus)


Juvenile myelomonocytic leukemia is a rare myeloproliferative disease in young children. While hematopoietic stem cell transplantation remains the only curative therapeutic option for most patients, children with juvenile myelomonocytic leukemia increasingly receive novel agents in phase I-II clinical trials as pre-transplant therapy or therapy for relapse after transplantation. However, response criteria or definitions of outcome for standardized evaluation of treatment effect in patients with juvenile myelomonocytic leukemia are currently lacking. Here we propose criteria to evaluate the response to the non-transplant therapy and definitions of remission status after hematopoietic stem cell transplantation. For the evaluation of non-transplant therapy, we defined 6 clinical variables (white blood cell count, platelet count, hematopoietic precursors and blasts in peripheral blood, bone marrow blast percentage, spleen size and extramedullary disease) and 3 genetic variables (cytogenetic, molecular and chimerism response) which serve to describe the heterogeneous picture of response to therapy in each individual case. It is hoped that these criteria will facilitate the comparison of results between clinical trials in juvenile myelomonocytic leukemia.

Originele taal-2Engels
Pagina's (van-tot)17-22
Aantal pagina's6
Nummer van het tijdschrift1
StatusGepubliceerd - 2015
Extern gepubliceerdJa


Duik in de onderzoeksthema's van 'Criteria for evaluating response and outcome in clinical trials for children with juvenile myelomonocytic leukemia'. Samen vormen ze een unieke vingerafdruk.

Citeer dit